Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On December 12, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for fiscal year 2025 that ended September 30, 2025 and provided a business update.</li><li>The company is continuing activities in preparation for an Investigational New Drug (IND) application submission with the U.S. FDA in order to initiate a Phase 2 trial of EB06 in vitiligo.</li><li>We anticipate patient enrollment initiating in mid-2026, contingent on the company completing manufacturing and regulatory activities.</li></ul>

On December 12, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for fiscal year 2025 that ended September 30, 2025 and provided a business update.The company is continuing activities in preparation for an Investigational New Drug (IND) application submission with the U.S. FDA in order to initiate a Phase 2 trial of EB06 in vitiligo.We anticipate patient enrollment initiating in mid-2026, contingent on the company completing manufacturing and regulatory activities.

EDSA: Gearing Up to Initiate Phase 2 Vitiligo Trial in Mid-2026